• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

花生四烯酸途径与人类肾细胞癌之间的关系。

Relationship between arachidonic acid pathway and human renal cell carcinoma.

作者信息

Matsuyama Masahide, Yoshimura Rikio

机构信息

Department of Urology, Osaka City University Graduate School of Medicine, Osaka City University Hospital, Abeno-ku, Osaka, Japan.

出版信息

Onco Targets Ther. 2008 Oct 1;1:41-8. doi: 10.2147/ott.s3973.

DOI:10.2147/ott.s3973
PMID:21127751
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2994214/
Abstract

Recent epidemiological studies and animal experiments have demonstrated that nonsteroidal antiinflammatory drugs (NSAIDs) reduce the incidence of colorectal carcinoma. Cyclooxygenase (COX) is the principal target of NSAIDs. COX is the first oxidase in the process of prostaglandin production from arachidonic acid. COX enzyme may be involved in the initiation and/or the promotion of carcinogenesis due to NSAIDs inhibition of COX. Lipoxygenase (LOX) is also an initial enzyme in the pathway for producing leukotrienes from arachidonic acid. Similar to COX, LOX enzyme may also be involved in the initiation and/or promotion of carcinogenesis. Peroxisome proliferator activator-receptor (PPAR)-γ is a ligand-activated transcriptional factor belonging to the steroid receptor superfamily. PPAR-γ plays a role in both adipocyte differentiation and carcinogenesis. PPAR-γ is one target for cell growth modulation of NSAIDs. In this review, we report the expression of COX-2, LOX and PPAR-γ in human renal cell carcinoma tissues as well as the effects of COX-2 and LOX inhibitors and PPAR-γ ligand.

摘要

近期的流行病学研究和动物实验表明，非甾体抗炎药（NSAIDs）可降低结直肠癌的发病率。环氧化酶（COX）是非甾体抗炎药的主要作用靶点。COX是花生四烯酸生成前列腺素过程中的首个氧化酶。由于非甾体抗炎药对COX的抑制作用，COX酶可能参与致癌作用的起始和/或促进过程。脂氧合酶（LOX）也是花生四烯酸生成白三烯途径中的起始酶。与COX类似，LOX酶也可能参与致癌作用的起始和/或促进过程。过氧化物酶体增殖物激活受体（PPAR）-γ是一种属于类固醇受体超家族的配体激活转录因子。PPAR-γ在脂肪细胞分化和致癌作用中均发挥作用。PPAR-γ是非甾体抗炎药调节细胞生长的一个靶点。在本综述中，我们报道了COX-2、LOX和PPAR-γ在人肾细胞癌组织中的表达情况，以及COX-2和LOX抑制剂及PPAR-γ配体的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ed5/2994214/dc0c960fda7b/ott_3973_relationship_between_arachidonic_acid_pathwayf5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ed5/2994214/8a5ed95db7af/ott_3973_relationship_between_arachidonic_acid_pathwayf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ed5/2994214/10572544c5c7/ott_3973_relationship_between_arachidonic_acid_pathwayf2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ed5/2994214/7d30e80d831f/ott_3973_relationship_between_arachidonic_acid_pathwayf3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ed5/2994214/6becfa1cdeb6/ott_3973_relationship_between_arachidonic_acid_pathwayf4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ed5/2994214/dc0c960fda7b/ott_3973_relationship_between_arachidonic_acid_pathwayf5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ed5/2994214/8a5ed95db7af/ott_3973_relationship_between_arachidonic_acid_pathwayf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ed5/2994214/10572544c5c7/ott_3973_relationship_between_arachidonic_acid_pathwayf2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ed5/2994214/7d30e80d831f/ott_3973_relationship_between_arachidonic_acid_pathwayf3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ed5/2994214/6becfa1cdeb6/ott_3973_relationship_between_arachidonic_acid_pathwayf4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ed5/2994214/dc0c960fda7b/ott_3973_relationship_between_arachidonic_acid_pathwayf5.jpg

相似文献

1
Relationship between arachidonic acid pathway and human renal cell carcinoma.花生四烯酸途径与人类肾细胞癌之间的关系。
Onco Targets Ther. 2008 Oct 1;1:41-8. doi: 10.2147/ott.s3973.
2
The target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer.花生四烯酸途径的靶向作用是一种针对人类前列腺癌的新抗癌策略。
Biologics. 2008 Dec;2(4):725-32. doi: 10.2147/btt.s3151.
3
Study of arachidonic Acid pathway in human bladder tumor.人膀胱肿瘤中花生四烯酸途径的研究。
Subst Abuse. 2009 Dec 9;3:99-107. doi: 10.4137/sart.s2151.
4
Arachidonic acid pathway: A molecular target in human testicular cancer (Review).花生四烯酸途径：人类睾丸癌的分子靶点（综述）。
Mol Med Rep. 2009 Jul-Aug;2(4):527-31. doi: 10.3892/mmr_00000131.
5
Honokiol inhibits gastric tumourigenesis by activation of 15-lipoxygenase-1 and consequent inhibition of peroxisome proliferator-activated receptor-gamma and COX-2-dependent signals.和厚朴酚通过激活 15-脂氧合酶-1 以及随后抑制过氧化物酶体增殖物激活受体-γ和 COX-2 依赖性信号来抑制胃肿瘤发生。
Br J Pharmacol. 2010 Aug;160(8):1963-72. doi: 10.1111/j.1476-5381.2010.00804.x.
6
[Relationship between cyclooxygenase (COX)-2 and malignant tumors].[环氧化酶（COX）-2与恶性肿瘤的关系]
Nihon Rinsho. 2005 Oct;63(10):1839-48.
7
Nimesulide, a preferential cyclooxygenase 2 inhibitor, suppresses peroxisome proliferator-activated receptor induction of cyclooxygenase 2 gene expression in human synovial fibroblasts: evidence for receptor antagonism.尼美舒利，一种选择性环氧化酶2抑制剂，可抑制人滑膜成纤维细胞中环氧化酶2基因表达的过氧化物酶体增殖物激活受体诱导：受体拮抗的证据。
Arthritis Rheum. 2002 Feb;46(2):494-506. doi: 10.1002/art.10055.
8
A novel approach to anticancer therapies: peroxisome proliferator activator-receptor-gamma as a new target therapy in the treatment of human urological cancer.一种抗癌治疗的新方法：过氧化物酶体增殖物激活受体γ作为治疗人类泌尿系统癌症的新靶向疗法。
Endocr Metab Immune Disord Drug Targets. 2009 Mar;9(1):76-83. doi: 10.2174/187153009787582432.
9
Epidermis-type lipoxygenase 3 regulates adipocyte differentiation and peroxisome proliferator-activated receptor gamma activity.表皮型脂氧合酶 3 调节脂肪细胞分化和过氧化物酶体增殖物激活受体 γ 的活性。
Mol Cell Biol. 2010 Aug;30(16):4077-91. doi: 10.1128/MCB.01806-08. Epub 2010 Jun 7.
10
Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma.通过同时靶向环氧化酶-2和过氧化物酶体增殖物激活受体γ抑制大鼠乳腺癌发生
Cancer Res. 2004 Feb 1;64(3):1181-9. doi: 10.1158/0008-5472.can-03-2556.

引用本文的文献

1
Lipids as Targets for Renal Cell Carcinoma Therapy.脂质作为肾癌治疗的靶点。
Int J Mol Sci. 2023 Feb 7;24(4):3272. doi: 10.3390/ijms24043272.
2
ELOVL5-mediated fatty acid elongation promotes cellular proliferation and invasion in renal cell carcinoma.ELOVL5 介导的脂肪酸延长促进肾细胞癌中的细胞增殖和侵袭。
Cancer Sci. 2022 Aug;113(8):2738-2752. doi: 10.1111/cas.15454. Epub 2022 Jun 24.
3
ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinoma.ELOVL2 通过抑制肾细胞癌中的细胞凋亡促进癌症进展。

本文引用的文献

1
Cyclooxygenase-2 expression: does it have a probable role in tumorigenesis mechanisms of renal cell carcinoma?环氧化酶-2表达：它在肾细胞癌的肿瘤发生机制中是否具有潜在作用？
Int Urol Nephrol. 2008;40(2):295-301. doi: 10.1007/s11255-007-9268-9.
2
Increased expression of 5-lipoxygenase is common in clear cell renal cell carcinoma.5-脂氧合酶表达增加在透明细胞肾细胞癌中很常见。
Histol Histopathol. 2007 Oct;22(10):1109-18. doi: 10.14670/HH-22.1109.
3
Overexpression of cysteinyl LT1 receptor in prostate cancer and CysLT1R antagonist inhibits prostate cancer cell growth through apoptosis.
Oncol Rep. 2022 Feb;47(2). doi: 10.3892/or.2021.8234. Epub 2021 Nov 29.
4
Synthesis and Biological Evaluation of -(5-(pyridin-2-yl)-1,3,4-thiadiazol-2-yl)benzamide Derivatives as Lipoxygenase Inhibitor with Potential Anticancer Activity.-（5-（吡啶-2-基）-1,3,4-噻二唑-2-基）苯甲酰胺衍生物作为具有潜在抗癌活性的脂氧合酶抑制剂的合成与生物学评价
Iran J Pharm Res. 2017 Winter;16(1):165-172.
5
Synthesis and evaluation of LOX inhibitory activity of 2-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-phenylacetamide derivatives.2-(1,3-二氧代-1H-苯并[de]异喹啉-2(3H)-基)-N-苯基乙酰胺衍生物的脂氧合酶抑制活性的合成与评价
Res Pharm Sci. 2016 Jul;11(4):265-73. doi: 10.4103/1735-5362.189283.
6
Arachidonic acid supplementation does not affect -methyl--nitrosourea-induced renal preneoplastic lesions in young Lewis rats.补充花生四烯酸对年轻Lewis大鼠中甲基亚硝基脲诱导的肾肿瘤前病变没有影响。
Oncol Lett. 2013 Apr;5(4):1112-1116. doi: 10.3892/ol.2013.1162. Epub 2013 Jan 30.
半胱氨酰白三烯1受体在前列腺癌中过表达，且半胱氨酰白三烯1受体拮抗剂通过诱导凋亡抑制前列腺癌细胞生长。
Oncol Rep. 2007 Jul;18(1):99-104.
4
Peroxisome proliferator-activated receptor gamma is frequently underexpressed in renal cell carcinoma.过氧化物酶体增殖物激活受体γ在肾细胞癌中常表达不足。
Int J Urol. 2006 Mar;13(3):265-70. doi: 10.1111/j.1442-2042.2006.01269.x.
5
Expression of COX-2 in normal and pyelonephritic kidney, renal intraepithelial neoplasia, and renal cell carcinoma.COX - 2在正常肾、肾盂肾炎肾、肾上皮内瘤变及肾细胞癌中的表达。
Eur Urol. 2006 Jul;50(1):92-7; discussion 97. doi: 10.1016/j.eururo.2005.12.039. Epub 2006 Jan 6.
6
Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma.转移性肾细胞癌中COX - 2的最大免疫染色以及对塞来昔布和α干扰素治疗的临床反应
Cancer. 2006 Feb 1;106(3):566-75. doi: 10.1002/cncr.21661.
7
5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway.5-脂氧合酶抑制剂通过花生四烯酸途径减弱人肾细胞癌的生长并诱导细胞凋亡。
Oncol Rep. 2005 Jul;14(1):73-9.
8
Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.过氧化物酶体增殖物激活受体γ配体诱导人肾癌细胞系的细胞周期停滞和凋亡。
Acta Pharmacol Sin. 2005 Jun;26(6):753-61. doi: 10.1111/j.1745-7254.2005.00753.x.
9
Ligands for peroxisome proliferator-activated receptor gamma have potent antitumor effect against human renal cell carcinoma.过氧化物酶体增殖物激活受体γ的配体对人肾细胞癌具有强大的抗肿瘤作用。
Urology. 2005 Mar;65(3):594-9. doi: 10.1016/j.urology.2004.10.019.
10
Comparative analysis of COX-2, vascular endothelial growth factor and microvessel density in human renal cell carcinomas.人肾细胞癌中COX-2、血管内皮生长因子及微血管密度的比较分析
Histopathology. 2004 Dec;45(6):603-11. doi: 10.1111/j.1365-2559.2004.02019.x.